Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $655

Author: Benzinga Newsdesk | February 06, 2024 11:45am
Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $605 to $655.

Posted In: IDXX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist